Sutro, Celgene in antibody deal

Sutro Biopharma Inc. (South San Francisco, Calif.) partnered with Celgene Corp. (NASDAQ:CELG) to design and develop antibody-drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets from Celgene for undisclosed indications. Sutro will be responsible for the design and the production of preclinical materials using its cell-free protein synthesis technology. Both companies are responsible for preclinical development, after which Celgene will be responsible for clinical development of any candidates. The deal also includes the manufacture of a separate, undisclosed "naked" Celgene antibody. ...